J. Hallet, C. H. Law, M. Cukier, R. Saskin, N. Liu et al., Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes, Cancer, vol.121, pp.589-97, 2015.

D. J. Kwekkeboom, W. W. De-herder, B. L. Kam, C. H. Van-eijck, M. Van-essen et al., Treatment with the radiolabeled somatostatin analog, J Clin Oncol, vol.26, pp.2124-2154, 2008.

G. Rindi, R. Arnold, F. T. Bosman, C. Capella, D. S. Klimstra et al., Nomenclature and classification of neuroendocrine neoplasms of the digestive system, WHO classification of tumours of the digestive system, pp.13-17, 2010.

U. Feine, R. Lietzenmayer, J. P. Hanke, J. Held, H. Wöhrle et al., Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer, J Nucl Med, vol.37, pp.1468-72, 1996.

H. H. Verbeek, J. T. Plukker, K. P. Koopmans, J. W. De-groot, R. M. Hofstra et al., Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma, J Nucl Med, vol.53, pp.1863-71, 2012.

F. L. Vélayoudom-céphise, P. Duvillard, L. Foucan, J. Hadoux, C. N. Chougnet et al., Are G3 ENETS neuroendocrine neoplasms heterogeneous?, Endocr Relat Cancer, vol.20, pp.649-57, 2013.

R. Abgral, S. Leboulleux, D. Déandreis, A. Aupérin, J. Lumbroso et al., Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (?10%) well-differentiated endocrine carcinoma staging, J Clin Endocrinol Metab, vol.96, pp.665-71, 2011.

I. Kayani, J. B. Bomanji, A. Groves, G. Conway, S. Gacinovic et al., Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG, Cancer, vol.112, pp.2447-55, 2008.

S. Severi, O. Nanni, L. Bodei, M. Sansovini, A. Ianniello et al., Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours, Eur J Nucl Med Mol Imaging, vol.40, pp.881-889, 2013.

G. Luo, Z. Liu, M. Guo, J. K. Xiao, Z. Liu et al., )F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors, Int J Oncol, vol.45, issue.18, pp.1531-1537, 2014.

S. Partelli, M. Rinzivillo, A. Maurizi, F. Panzuto, M. Salgarello et al., The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors, Neuroendocrinology, vol.100, pp.293-302, 2014.

A. Asnacios, F. Courbon, P. Rochaix, E. Bauvin, V. Cances-lauwers et al., Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors, J Clin Oncol, vol.26, pp.963-70, 2008.

. Emc--radiologie,

, Techniques de médecine nucléaire pour l'imagerie et le traitement des tumeurs neuroendocrines gastro-entéro-pancréatiques

S. Ezziddin, L. Adler, A. Sabet, T. D. Pöppel, F. Grabellus et al., Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system, J Nucl Med, vol.55, pp.1260-1266, 2014.

E. Garin, L. Jeune, F. Devillers, A. Cuggia, M. De-lajarte-thirouard et al., Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors, J Nucl Med, vol.50, pp.858-64, 2009.

H. Bahri, L. Laurence, E. J. Leghzali, H. Devillers, A. Raoul et al., High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation, J Nucl Med, vol.55, pp.1786-90, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01132696

H. Minn, S. Kauhanen, M. Seppänen, and P. Nuutila, 18F-FDOPA: a multipletarget molecule, J Nucl Med, vol.50, pp.1915-1923, 2009.

D. Taïeb, H. J. Timmers, E. Hindié, B. A. Guillet, H. P. Neumann et al., EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma, Eur J Nucl Med Mol Imaging, vol.39, pp.1977-95, 2012.

K. P. Koopmans, E. G. De-vries, I. P. Kema, P. H. Elsinga, O. C. Neels et al., Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study, Lancet Oncol, vol.7, pp.728-762, 2006.

F. Montravers, D. Grahek, K. Kerrou, P. Ruszniewski, V. De-beco et al., Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?, J Nucl Med, vol.47, pp.1455-62, 2006.

S. Balogova, J. N. Talbot, V. Nataf, L. Michaud, V. Huchet et al., 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type, Eur J Nucl Med Mol Imaging, vol.40, pp.943-66, 2013.

F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J. P. Lotz et al., Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors, J Clin Endocrinol Metab, vol.94, pp.1295-301, 2009.

A. Imperiale, E. Rust, S. Gabriel, J. Detour, B. Goichot et al., 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation, J Nucl Med, vol.55, pp.367-72, 2014.

H. B. Fiebrich, J. R. De-jong, I. P. Kema, K. P. Koopmans, W. Sluiter et al., Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour, Eur J Nucl Med Mol Imaging, vol.38, pp.1854-61, 2011.

B. A. Blomberg, M. C. Moghbel, B. Saboury, C. A. Stanley, and A. Alavi, The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis, Mol Imaging Biol, vol.15, pp.97-105, 2013.

A. Imperiale, F. Sebag, M. Vix, F. Castinetti, L. Kessler et al., 18F-FDOPA PET/CT imaging of insulinoma revisited, Eur J Nucl Med Mol Imaging, vol.42, pp.409-427, 2015.

S. Kauhanen, M. Seppanen, and P. Nuutila, Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [18F]-dihydroxy-phenyl-alanine positron emission tomography, J Clin Oncol, vol.26, pp.5307-5315, 2008.

V. Ambrosini, P. Tomassetti, P. Castellucci, D. Campana, G. Montini et al., Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours, Eur J Nucl Med Mol Imaging, vol.35, pp.1431-1439, 2008.

A. Haug, C. J. Auernhammer, B. Wängler, R. Tiling, G. Schmidt et al., Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours, Eur J Nucl Med Mol Imaging, vol.36, pp.765-70, 2009.

E. P. Krenning, D. J. Kwekkeboom, W. H. Bakker, W. A. Breeman, P. P. Kooij et al., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients, Eur J Nucl Med, vol.20, pp.716-747, 1993.

E. Bombardieri, V. Ambrosini, C. Aktolun, R. P. Baum, A. Bishof-delaloye et al., 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging, Eur J Nucl Med Mol Imaging, vol.37, pp.1441-1449, 2010.

M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute et al., 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT, J Nucl Med, vol.48, pp.508-526, 2007.

V. Ambrosini, C. Nanni, M. Zompatori, D. Campana, P. Tomassetti et al., Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, vol.37, issue.68, pp.722-729, 2010.

H. Geijer and L. H. Breimer, Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis, Eur J Nucl Med Mol Imaging, vol.40, pp.1770-80, 2013.

H. Ilhan, W. P. Fendler, C. C. Cyran, C. Spitzweg, C. J. Auernhammer et al., Impact of 68Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum, Ann Surg Oncol, vol.22, pp.164-71, 2015.

R. Kumar, P. Sharma, P. Garg, S. Karunanithi, N. Naswa et al., Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours, Eur Radiol, vol.21, pp.2408-2424, 2011.

C. Schmid-tannwald, C. M. Schmid-tannwald, J. N. Morelli, R. Neumann, A. R. Haug et al., Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas, Eur J Nucl Med Mol Imaging, vol.40, pp.897-907, 2013.

P. Sharma, S. Arora, V. S. Dhull, N. Naswa, R. Kumar et al., Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors, Abdom Imaging, vol.40, pp.299-309, 2015.

J. Bertherat, F. Tenenbaum, K. Perlemoine, C. Videau, J. L. Alberini et al., Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study, J Clin Endocrinol Metab, vol.88, pp.5353-60, 2003.

D. Wild, E. Christ, M. E. Caplin, T. R. Kurzawinski, F. Forrer et al., Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas, J Nucl Med, vol.52, pp.1073-1081, 2011.

N. Naswa, P. Sharma, R. Soundararajan, S. Karunanithi, A. H. Nazar et al., Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings, Abdom Imaging, vol.38, pp.552-60, 2013.

V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti et al., Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT, Eur J Nucl Med Mol Imaging, vol.37, pp.67-77, 2010.

N. Naswa, P. Sharma, A. Kumar, R. Soundararajan, R. Kumar et al., 68Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin, Clin Nucl Med, vol.37, pp.245-51, 2012.

O. Alonso, M. Rodríguez-taroco, E. Savio, C. Bentancourt, J. P. Gambini et al., Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin, Ann Nucl Med, vol.28, issue.68, pp.638-683, 2014.

T. H. Tan, B. N. Lee, and S. Z. Hassan, Diagnostic value of (68)Ga-DOTATATE PET/CT in liver metastases of neuroendocrine tumours of unknown origin, Nucl Med Mol Imaging, vol.48, pp.212-217, 2014.

V. Ambrosini, D. Campana, L. Bodei, C. Nanni, P. Castellucci et al., 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors, J Nucl Med, vol.51, pp.669-73, 2010.

P. Sharma, N. Naswa, S. S. Kc, L. A. Alvarado, A. K. Dwivedi et al., Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor, Eur J Nucl Med Mol Imaging, vol.41, pp.2194-202, 2014.

J. P. Pouget, I. Navarro-teulon, M. Bardiès, N. Chouin, G. Cartron et al., Clinical radioimmunotherapy-the role of radiobiology, Nat Rev Clin Oncol, vol.8, pp.8720-8754, 2011.

S. Paillas, V. Boudousq, B. Piron, N. Kersual, M. Bardiès et al., Apoptosis and p53 are not involved in the anti-tumor efficacy of 125 Ilabeled monoclonal antibodies targeting the cell membrane, Nucl Med Biol, vol.40, pp.471-80, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00815724

D. Brady, J. M. O'sullivan, and K. M. Prise, What is the role of the bystander response in radionuclide therapies?, Front Oncol, vol.3, p.215, 2013.

G. Sgouros, S. J. Knox, M. C. Joiner, W. F. Morgan, and A. I. Kassis, MIRD continuing education: bystander and low dose-rate effects: are these relevant to radionuclide therapy?, J Nucl Med, vol.48, pp.1683-91, 2007.

S. D. Safford, R. E. Coleman, J. P. Gockerman, J. Moore, J. Feldman et al., Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients, Cancer, vol.101, pp.1987-93, 2004.

R. Valkema, D. Jong, M. Bakker, W. H. Breeman, W. A. Kooij et al., Phase I study of peptide receptor radionuclide therapy with, Semin Nucl Med, vol.32, pp.110-132, 2002.

R. Valkema, S. Pauwels, L. K. Kvols, R. Barone, J. F. Bakker et al., Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors, Semin Nucl Med, vol.36, pp.147-56, 2006.

G. Paganelli, M. Sansovini, A. Ambrosetti, S. Severi, M. Monti et al., 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study, Eur J Nucl Med Mol Imaging, vol.41, pp.1845-51, 2014.

R. Kashyap, M. S. Hofman, M. Michael, G. Kong, T. Akhurst et al., Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

, Eur J Nucl Med Mol Imaging, vol.42, pp.176-85, 2015.

E. Seregni, M. Maccauro, C. Chiesa, L. Mariani, C. Pascali et al., Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy, Eur J Nucl Med Mol Imaging, vol.41, pp.223-253, 2014.

S. Khan, E. P. Krenning, M. Van-essen, B. L. Kam, and J. J. Teunissen, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3] octreotate, J Nucl Med, vol.52, pp.1361-1369, 2011.

R. P. Baum, H. R. Kulkarni, and C. Carreras, Peptides and receptors in imageguided therapy: theranostics for neuroendocrine neoplasms, Semin Nucl Med, vol.42, pp.190-207, 2012.

L. Bodei, M. Cremonesi, M. Ferrari, M. Pacifici, C. M. Grana et al., Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors, Eur J Nucl Med Mol Imaging, vol.35, pp.1847-56, 2008.

L. Bodei, M. Kidd, G. Paganelli, C. M. Grana, I. Drozdov et al., Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors, Eur J Nucl Med Mol Imaging, vol.42, pp.5-19, 2015.

S. Ezziddin, M. Opitz, M. Attassi, K. Biermann, A. Sabet et al., Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy, Eur J Nucl Med Mol Imaging, vol.38, pp.459-66, 2011.

A. Sowa-staszczak, A. Hubalewska-dydejczyk, and M. Tomaszuk, PRRT as neoadjuvant treatment in NET, Recent Results Cancer Res, vol.194, pp.479-85, 2013.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), Eur J Cancer, vol.45, pp.228-275, 2009.

R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, pp.122-50, 2009.

P. Y. Salaun, L. Campion, C. Ansquer, E. Frampas, C. Mathieu et al., 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma, Eur J Nucl Med Mol Imaging, vol.41, pp.1501-1511, 2014.

A. R. Haug, C. J. Auernhammer, B. Wängler, G. P. Schmidt, C. Uebleis et al., 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors, J Nucl Med, vol.51, pp.1349-56, 2010.

, Pour en savoir plus

F. Bodéré, E. Garin, and J. P. Vuillez, Radiopharmaceutiques à visée thérapeutique : indications, précautions d'emploi et principaux résultats. EMC Radiologie et imagerie médicale : principes et techniques -Radioprotection, 2013.

, Thésaurus national de cancérologie digestive : www.tncd.Org

C. Ansquer, MD (catherine.ansquer@chu-nantes.fr)

, Inserm UMR892, 8, quai Moncousu, BP 70721, 44007 Nantes cedex, France. F. Kraeber-Bodéré, MD, PhD. Service de médecine nucléaire, Centre hospitalier universitaire Hôtel-Dieu, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France. Centre régional de recherche en cancérologie Nantes/Angers (CRCNA), EMC -Radiologie et imagerie médicale -abdominale -digestive, vol.11, issue.3, pp.1-11, 2016.